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We aimed to derive and validate a triage tool, based on clinical assessment alone, for pre-
dicting adverse outcome in acutely ill adults with suspected COVID-19 infection.
Methods
We undertook a mixed prospective and retrospective observational cohort study in 70 emer-
gency departments across the United Kingdom (UK). We collected presenting data from
22445 people attending with suspected COVID-19 between 26 March 2020 and 28 May
2020. The primary outcome was death or organ support (respiratory, cardiovascular, or
renal) by record review at 30 days. We split the cohort into derivation and validation sets,
developed a clinical score based on the coefficients frommultivariable analysis using the
derivation set, and the estimated discriminant performance using the validation set.
Results
We analysed 11773 derivation and 9118 validation cases. Multivariable analysis identified
that age, sex, respiratory rate, systolic blood pressure, oxygen saturation/inspired oxygen
ratio, performance status, consciousness, history of renal impairment, and respiratory dis-
tress were retained in analyses restricted to the ten or fewer predictors. We used findings
frommultivariable analysis and clinical judgement to develop a score based on the NEWS2
score, age, sex, and performance status. This had a c-statistic of 0.80 (95% confidence
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interval 0.79–0.81) in the validation cohort and predicted adverse outcome with sensitivity
0.98 (0.97–0.98) and specificity 0.34 (0.34–0.35) for scores above four points.
Conclusion
A clinical score based on NEWS2, age, sex, and performance status predicts adverse out-
come with good discrimination in adults with suspected COVID-19 and can be used to sup-
port decision-making in emergency care.
Registration
ISRCTN registry, ISRCTN28342533, http://www.isrctn.com/ISRCTN28342533
Introduction
The initial management of acutely ill people with suspected COVID-19 involves assessing the
risk of adverse outcome and the need for life-saving intervention, to then determine decisions
around hospital admission and inpatient referral [1–5]. Triage tools can assist decision-making
by combining information from clinical assessment in a structured manner to predict the risk
of adverse outcome. They can take the form of a score that increases with the predicted risk of
adverse outcome or a rule that categorises patients into groups according to their risk or their
intended management. Inclusion of laboratory and radiological information can improve pre-
diction but requires hospital attendance, increases emergency department (ED) length of stay,
and increases the infection risk related to repeated patient contacts. Triage tools also need to
be applied prospectively to the relevant patient group, using the information available at the
time of presentation. The limited availability of rapid tests with sufficient sensitivity to rule out
COVID-19 at initial assessment means that the relevant population is suspected rather than
confirmed COVID-19. An appropriate triage tool for COVID-19 therefore needs to be based
on clinical assessment alone and applicable to people with suspected COVID-19.
We designed the Pandemic Influenza Triage in the Emergency Department (PAINTED)
study following the 2009 H1N1 influenza pandemic to develop and evaluate triage tools in any
future influenza pandemic [6]. We changed PAINTED to the Pandemic Respiratory Infection
Emergency System Triage (PRIEST) study in January 2020 to address any pandemic respiratory
infection, including COVID-19. The United Kingdom (UK) Department of Health and Social
Care activated PRIEST on 20 March 2020 to develop and evaluate triage tools in the COVID-19
pandemic. Initial descriptive analysis of the PRIEST data showed that adults presenting to the
ED with suspected COVID-19 have much higher rates of COVID-19 positivity, hospital admis-
sion and adverse outcome than children [7]. We therefore decided to undertake separate studies
in adults and children, and only develop a new triage tools in adults, which we present here.
Evaluation of existing triage tools using the PRIEST study data suggested that CURB-65 [8],
the National Early Warning Score version 2 (NEWS2) [9] and the Pandemic Modified Early
Warning Score (PMEWS) [10] provide reasonable prediction for adverse outcome in sus-
pected COVID-19 (c-statistics 0.75 to 0.77) [11]. Scope therefore existed to develop a specific
triage tool for COVID-19 with better prediction for adverse outcome.
We aimed to derive and validate a triage tool in the form of an illness severity score, based
on clinical assessment alone, for predicting adverse outcome in acutely ill adults with sus-
pected COVID-19 infection.
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Materials andmethods
We designed PRIEST as an observational study to collect standardised predictor variables
recorded in the ED, which we would then use to derive and validate new tools for predicting
adverse outcome up to 30 days after initial hospital presentation. The study did not involve
any change to patient care. Hospital admission and discharge decisions were made according
to usual practice, informed by local and national guidance.
We identified consecutive patients presenting to the ED of participating hospitals with sus-
pected COVID-19 infection. Patients were eligible if they met the clinical diagnostic criteria
[12] of fever (�37.8˚C) and acute onset of persistent cough (with or without sputum), hoarse-
ness, nasal discharge or congestion, shortness of breath, sore throat, wheezing, or sneezing.
This was determined on the basis of the assessing clinician recording that the patient had sus-
pected COVID-19 or completing a standardised assessment form designed for suspected pan-
demic respiratory infection [6]. During the study period COVID-19 testing was only
recommended for those admitted to hospital, so it was recorded as a descriptive variable but
not used to select patients or in the analysis.
For this study we planned to develop a triage tool in the form of an illness severity score
based on clinical assessment and routine observations that any health care professional could
use to rapidly estimate the risk of adverse outcome. The score would be based on a number
of categorised variables, with points allocated to each category of each variable, which would
then be summed to give a total score reflecting the predicted risk of adverse outcome. To
enhance usability, we planned to (a) use a restricted number of variables, rather than all
potentially predictive variables, and (b) categorise variables in accordance with currently
used scores, unless there was clear evidence that these categories provided suboptimal
prediction.
Data collection was both prospective and retrospective. Participating EDs were provided
with a standardised data collection form (S1 Appendix) that included variables used in exist-
ing triage tools or considered to be potentially useful predictors of adverse outcome. Partici-
pating sites could adapt the form to their local circumstances, including integrating it into
electronic or paper clinical records to facilitate prospective data collection, or using it as a
template for research staff to retrospectively extract data from clinical records. We did not
seek consent to collect data but information about the study was provided in the ED and
patients could withdraw their data at their request. Patients with multiple presentations to
hospital were only included once, using data from the first presentation identified by
research staff.
Research staff at participating hospitals reviewed patient records at 30 days after initial
attendance and recorded outcomes using the follow-up form in S2 Appendix. The primary
outcome was death or major organ support (respiratory, cardiovascular, or renal) up to 30
days after initial attendance. Death and major organ support were also analysed separately as
secondary outcomes. Our primary outcome definition reflected the need for triage tools to
identify patients at risk of adverse outcome or requiring life-saving intervention to prevent
adverse outcome. Respiratory support was defined as any intervention to protect the
patient’s airway or assist their ventilation, including non-invasive ventilation or acute
administration of continuous positive airway pressure. It did not include supplemental
oxygen alone or nebulised bronchodilators. Cardiovascular support was defined as any inter-
vention to maintain organ perfusion, such as inotropic drugs, or invasively monitor cardio-
vascular status, such as central venous pressure or pulmonary artery pressure monitoring, or
arterial blood pressure monitoring. It did not include peripheral intravenous cannulation or
fluid administration. Renal support was defined as any intervention to assist renal function,
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such as haemofiltration, haemodialysis, or peritoneal dialysis. It did not include intravenous
fluid administration.
We randomly split the study population into derivation and validation cohorts by randomly
allocating the participating sites to one or other cohort. We developed a score based on the
prognostic value of predictor variables in multivariable analysis of the derivation cohort and
expert judgements regarding clinical usability. Candidate predictors were combined in a mul-
tivariable regression with Least Absolute Shrinkage and Selection Operator (LASSO) using ten
sample cross validation to select the model. The LASSO begins with a full model of candidate
predictors and simultaneously performs predictor selection and penalisation during model
development to avoid overfitting. The LASSO was performed twice: once where the number of
predictors were unrestricted, and a second time when the LASSO was restricted to pick ten
predictors. Fractional polynomials were used to model non-linear relationships for continuous
variables.
We excluded cases from all analyses if age or outcome data were missing. We undertook
three multivariable analyses, using different approaches to missing predictor variable data in
the derivation cohort: (1) Complete case; (2) Multiple imputation using chained equations; (3)
Deterministic imputation with missing predictor data assumed to be normal, where applicable.
We did not consider any predictor with more than 50% missing data across the cohort for
inclusion in the predictive model.
Clinical members of the research team reviewed the models and selected variables for inclu-
sion in the triage tool, based on their prognostic value in the model, the clinical credibility of
their association with adverse outcome, and their availability in routine clinical care. We cate-
gorised continuous variables, using recognised categories from existing scores where appropri-
ate, while checking that categorisation reflected the relationship between the variable and
adverse outcome in the derivation data. We then assigned integer values to each category of
predictor variable, taking into account the points allocated to the category in existing scores,
and the coefficient derived from a multivariable logistic regression model using categorised
continuous predictors. This generated a composite clinical score in which risk of adverse out-
come increased with the total score.
We applied the clinical score to the validation cohort, calculating diagnostic parameters at
each threshold of the score, constructing a receiver-operating characteristic (ROC) curve, cal-
culating the area under the ROC curve (c-statistic) and calculating the proportion with an
adverse outcome at each level of the score. We used deterministic imputation to handle miss-
ing data in the validation cohort, assuming missing predictor variable data were normal, but
excluding cases with more than a pre-specified number of predictor variables missing. We also
undertook a complete case sensitivity analysis.
The sample size was dependent on the size and severity of the pandemic, but based on a
previous study in the 2009 H1N1 influenza pandemic we estimated we would need to collect
data from 20,000 patients across 40–50 hospitals to identify 200 (1%) with an adverse outcome,
giving sufficient power for model derivation. In the event, the adverse outcome rate in adults
was much higher in the COVID-19 pandemic (22%) [7], giving us adequate power to under-
take derivation and validation of triage tools to predict all three outcomes.
Patient and public involvement
The Sheffield Emergency Care Forum (SECF) is a public representative group interested in
emergency care research [13]. Members of SECF advised on the development of the PRIEST
study and two members joined the Study Steering Committee. Patients were not involved in
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the recruitment to and conduct of the study. We are unable to disseminate the findings to
study participants directly.
Ethical approval
The North West—Haydock Research Ethics Committee gave a favourable opinion on the
PAINTED study on 25 June 2012 (reference 12/NW/0303) and on the updated PRIEST study
on 23rd March 2020, including the analysis presented here. The Confidentiality Advisory
Group of the Health Research Authority granted approval to collect data without patient con-
sent in line with Section 251 of the National Health Service Act 2006.
Results
The PRIEST study recruited 22485 patients from 70 EDs across 53 sites between 26 March
2020 and 28 May 2020. We included 20889 in the analysis after excluding 39 who requested
withdrawal of their data, 1530 children, 20 with missing outcome data, and seven with missing
age. The derivation cohort included 11773 patients and the validation cohort 9118. Table 1
shows the characteristics of the derivation and validation cohorts. Around 31% of each cohort
had COVID-19 confirmed, reflecting a combination of lack of testing in those discharged, sub-
optimal sensitivity of standard tests, and the difficulty of differentiating COVID-19 from simi-
lar presentations.
Table 2 shows summary statistics for each predictor variable in those with and without
adverse outcome in the derivation sample, and univariate odds ratios for prediction of adverse
outcome. Physiological variables were categorised to reflect their expected relationships with
adverse outcome.
S1–S3 Tables show the results of multivariable analysis using complete case analysis, multi-
ple imputation and deterministic imputation. Unrestricted LASSO on multiply imputed data
included more predictors, with a higher c-statistic for the model (0.85, 95% CI 0.84 to 0.86),
than the LASSO on deterministically imputed data or complete cases (c-statistics both 0.83,
95% CI 0.82 to 0.84). When restricted, there were nine predictors that were retained by LASSO
in all three analyses (age, sex, respiratory rate, systolic BP, oxygen saturation/inspired oxygen
ratio, history of renal impairment, performance status, consciousness and respiratory distress).
C-statistics for the restricted models using deterministic imputation and complete case analy-
sis (0.82, 95% CI 0.81 to 0.83) were slightly lower than c-statistics for the respective unre-
stricted models.
We developed a score through the following steps:
1. Clinical review judged that the nine predictors are clinically credible; that age, sex, respira-
tory rate, systolic BP, consciousness, oxygen saturation and inspired oxygen are routinely
recorded in administrative systems and early warning scores (although the ratio of oxygen
saturation to inspired oxygen is not routinely recorded); and that many EDs routinely
record a measure of performance status for suspected COVID-19 cases that could be
mapped onto our scale.
2. We decided to include temperature and heart rate, as these are routinely recorded alongside
other physiological variables in early warning scores, and added prognostic value in the full
models.
3. We created categories for age based on the observed multivariate association between age
and outcome in our data, and categories for respiratory rate, heart rate, oxygen saturation,
inspired oxygen, systolic BP, consciousness and temperature based on those used in the
NEWS2 early warning score. NEWS2 is outlined in S3 Appendix.
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Table 1. Characteristics of the study population (derivation and validation cohorts).
Characteristic Statistic/level Derivation Validation
Age (years) N 11773 9118
Mean (SD) 62.4 (19.9) 62.4 (19.5)
Median (IQR) 64 (48,79) 64 (48,79)
Sex Missing 137 56
Male 5746 (49.4%) 4455 (49.2%)
Female 5890 (50.6%) 4607 (50.8%)
Ethnicity Missing/prefer not to say 1819 2379
UK/Irish/other white 8376 (84.1%) 5867 (87.1%)
Asian 699 (7%) 345 (5.1%)
Black/African/Caribbean 368 (3.7%) 272 (4%)
Mixed/multiple ethnic groups 178 (1.8%) 69 (1%)
Other 333 (3.3%) 186 (2.8%)
Presenting features Cough 7248 (61.6%) 5737 (62.9%)
Shortness of breath 8570 (72.8%) 7000 (76.8%)
Fever 5714 (48.5%) 4562 (50%)
Comorbidities Hypertension 3627 (30.8%) 2807 (30.8%)
Heart Disease 2512 (21.3%) 2188 (24%)
Diabetes 2394 (20.3%) 1735 (19%)
Asthma 1867 (15.9%) 1541 (16.9%)
Other chronic lung disease 2047 (17.4%) 1717 (18.8%)
Renal impairment 1074 (9.1%) 856 (9.4%)
Active malignancy 577 (4.9%) 543 (6%)
Immunosuppression 312 (2.7%) 319 (3.5%)
Steroid therapy 303 (2.6%) 254 (2.8%)
No chronic disease 3385 (28.8%) 2406 (26.4%)
Symptom duration (days) N 10790 8087
Mean (SD) 8.1 (9.1) 7.6 (8.6)
Median (IQR) 5 (2,10) 5 (2,10)
Heart rate (beats/min) N 11506 8954
Mean (SD) 94.7 (21.5) 95.2 (21.7)
Median (IQR) 93 (80,108) 94 (80,109)
Respiratory rate (breaths/min) N 11438 8908
Mean (SD) 23.1 (6.9) 23.4 (7.1)
Median (IQR) 22 (18,26) 22 (18,26)
Systolic BP (mmHg) N 11423 8875
Mean (SD) 134.5 (24.9) 134.8 (25)
Median (IQR) 133 (118,149) 133 (118,150)
Diastolic BP (mmHg) N 11373 8839
Mean (SD) 78.3 (15.8) 78.2 (16.5)
Median (IQR) 78 (68,88) 78 (68,88)
Temperature (˚C) N 11307 8924
Mean (SD) 37.1 (1.1) 37.2 (1.1)
Median (IQR) 37 (36.4,37.8) 37 (36.5,37.9)
Oxygen saturation (%) N 11658 8974
Mean (SD) 94.9 (6.2) 94.4 (7.5)
Median (IQR) 96 (94,98) 96 (94,98)
Air or supplementary oxygen Missing 4113 4735
(Continued)
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4. We created a multivariable logistic regression model using categorised predictor variables
(S4 Table) and compared the coefficients for each category of predictor variable in the
NEWS2 score to the points allocated in the NEWS2 score. We judged that the inconsisten-
cies between the coefficients and the points used in NEWS2 were insufficient to justify
Table 1. (Continued)
Characteristic Statistic/level Derivation Validation
On air 5243 (68.4%) 2544 (58%)
On supplementary oxygen 2417 (31.6%) 1839 (42%)
Supplementary inspired oxygen (%) N 2417 1839
Mean (SD) 45.9 (21.9) 48.6 (22.5)
Median (IQR) 36 (28,60) 36 (28,80)
Glasgow Coma Scale N 8627 6801
Mean (SD) 14.6 (1.4) 14.6 (1.4)
Median (IQR) 15 (15,15) 15 (15,15)
Consciousness Missing 1515 872
Alert 9774 (95.3%) 7794 (94.5%)
Verbal 333 (3.2%) 307 (3.7%)
Pain 101 (1%) 82 (1%)
Unresponsive 50 (0.5%) 63 (0.8%)
Performance status Missing 620 458
1. Unrestricted normal activity 5989 (53.7%) 4547 (52.5%)
2. Limited strenuous activity, can do light activity 1315 (11.8%) 1056 (12.2%)
3. Limited activity, can self-care 1565 (14%) 1211 (14%)
4. Limited self-care 1494 (13.4%) 1155 (13.3%)
5. Bed/chair bound, no self-care 790 (7.1%) 691 (8%)
Admitted at initial assessment Missing 7 21
No 3744 (31.8%) 3122 (34.3%)
Yes 8022 (68.2%) 5975 (65.7%)
Location of first admission† Missing 173 159
Ward 7238 (92.2%) 5409 (93%)
ITU 479 (6.1%) 311 (5.3%)
HDU 132 (1.7%) 96 (1.7%)
Respiratory pathogen COVID-19 3660 (31.1%) 2861 (31.4%)
Influenza 2 (0%) 25 (0.3%)
Other 912 (7.7%) 809 (8.9%)
None identified 7199 (61.1%) 5423 (59.5%)
Mortality status Missing 0 3
Alive 10002 (85%) 7640 (83.8%)
Dead 1771 (15%) 1475 (16.2%)
Death with organ support� 326 (18.4%) 367 (24.9%)
Death with no organ support� 1445 (81.6%) 1108 (75.1%)
Organ support Respiratory 939 (8%) 1005 (11%)
Cardiovascular 316 (2.7%) 201 (2.2%)
Renal 104 (0.9%) 114 (1.3%)
Any 999 (8.5%) 1059 (11.6%)
� Denominator total deaths in category
† Denominator admitted patients
https://doi.org/10.1371/journal.pone.0245840.t001
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Table 2. Univariate analysis of predictor variables for adverse outcome (derivation cohort).
Predictor Variable Category (categorical variables) n (outcome) Odds ratio p-value 95% CI
Adverse Non adverse
Age (n = 11773) 1.04 0.00 (1.04, 1.04)
Sex (n = 11636) Ref = Female 1008 4882
Male 1413 4333 1.58 0.000 (1.44, 1.73)
Ethnicity Category (n = 9954) Ref = UK/Irish/other white 1767 6609
Asian 138 561 0.92 0.399 (0.76, 1.12)
Black/African/Caribbean 72 296 0.91 0.481 (0.70, 1.18)
Mixed/multiple ethnic groups 28 150 0.70 0.084 (0.46, 1.05)
Other 39 294 0.50 0.000 (0.35, 0.70)
Shortness of breath (n = 11746) Ref = No 536 2640
Yes 1896 6674 1.40 0.000 (1.26, 1.56)
Cough (n = 11746) Ref = No 1065 3433
Yes 1367 5881 0.75 0.000 (0.68, 0.82)
Fever (n = 11746) Ref = No 1274 4758
Yes 1158 4556 0.95 0.253 (0.87, 1.04)
Hypertension (n = 11732) Ref = No 1445 6660
Yes 995 2632 1.74 0.000 (1.59, 1.91)
Heart Disease (n = 11732) Ref = No 1680 7540
Yes 760 1752 1.95 0.000 (1.76, 2.15)
Diabetes (n = 11732) Ref = No 1733 7605
Yes 707 1687 1.84 0.000 (1.66, 2.04)
Asthma (n = 11732) Ref = No 2143 7722
Yes 297 1570 0.68 0.000 (0.60, 0.78)
Other chronic lung disease (n = 11732) Ref = No 1919 7766
Yes 521 1526 1.38 0.000 (1.24, 1.54)
Renal impairment (n = 11732) Ref = No 2051 8607
Yes 389 685 2.38 0.000 (2.09, 2.72)
Active malignancy (n = 11732) Ref = No 2248 8907
Yes 192 385 1.98 0.000 (1.65, 2.36)
Immunosuppression (n = 11732) Ref = No 2360 9060
Yes 80 232 1.32 0.033 (1.02, 1.71)
Steroid therapy (n = 11732) Ref = No 2363 9066
Yes 77 226 1.31 0.046 (1.01, 1.70)
Symptom duration (n = 10790) 0.97 0.000 (0.96, 0.98)
Number current medications (n = 11183) 1.09 0.00 (1.08, 1.10)
Respiratory rate (n = 11773) Ref = 12–20 or missing 644 5061
<9 3 5 4.72 0.034 (1.12, 19.78)
9–11 3 8 2.95 0.111 (0.78, 11.14)
21–24 581 2191 2.08 0.000 (1.84, 2.36)
>24 1213 2064 4.62 0.000 (4.14, 5.15)
Systolic Blood Pressure (n = 11773) Ref = 111–219 or missing 1860 8093
101–110 269 745 1.57 0.000 (1.35, 1.82)
91–100 170 320 2.31 0.000 (1.91, 2.80)
<91 137 143 4.17 0.000 (3.28, 5.30)
>219 8 28 1.24 0.588 (0.57, 2.73)
Heart rate (n = 11773) Ref = 51–90 or missing 1007 4353
<41 15 42 1.54 0.152 (0.85, 2.79)
(Continued)
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allocating alternative points in our score. We allocated points to categories of age, sex, per-
formance status, renal history, and respiratory distress, based on the coefficients in the
model.
5. We removed renal history and respiratory distress from the multivariable model (S5 Table),
noted that this made no meaningful difference to the c-statistic (0.82 in both models) and,
given concerns about subjectivity and lack of routine recording, decided not to include
them in the score.
Fig 1 provides a summary of the derivation process. The developed score is shown in Fig 2.
We applied the score to the validation cohort. Fig 3 shows the ROC curve, with a c-statistic of
0.80 (95% CI 0.79 to 0.81) for the score. Sensitivity analysis using only complete cases gave a c-
statistic of 0.79 (95% CI 0.77 to 0.80). S1 and S2 Figs show the calibration plots for the
Table 2. (Continued)
Predictor Variable Category (categorical variables) n (outcome) Odds ratio p-value 95% CI
Adverse Non adverse
41–50 12 42 1.24 0.521 (0.65, 2.35)
91–110 776 3112 1.08 0.159 (0.97, 1.20)
111–130 450 1367 1.42 0.000 (1.25, 1.62)
>130 184 413 1.93 0.000 (1.60, 2.32)
Temperature (n = 11773) Ref = 36.1–38.0 or missing 1498 6747
35.1–36 245 958 1.15 0.067 (0.99, 1.34)
38.1–39 446 1137 1.77 0.000 (1.56, 2.00)
>39.0 166 386 1.94 0.000 (1.60, 2.34)
<35.1 89 101 3.97 0.000 (2.97, 5.31)
GCS Total (n = 8627) Ref = Mild (13–15) 1551 6618
Moderate (9–12) 187 150 5.32 0.000 (4.26, 6.64)
Severe (< = 8) 73 48 6.49 0.000 (4.49, 9.38)
AVPU (n = 10258) Ref = Alert 1756 8018
Verbal 176 157 5.12 0.000 (4.10, 6.39)
Pain 62 39 7.26 0.000 (4.85, 10.87)
Unresponsive 32 18 8.12 0.000 (4.55, 14.49)
Performance status (n = 11153) Ref = Unrestricted normal activity 709 5280
Limited strenuous activity, can do light activity 268 1047 1.91 0.000 (1.63, 2.23)
Limited activity, can self care 430 1135 2.82 0.000 (2.46, 3.23)
Limited self care 560 934 4.47 0.000 (3.92, 5.09)
Bed/chair bound, no self care 334 456 5.45 0.000 (4.64, 6.41)
Severe respiratory distress (n = 11773) Ref = No 2250 9184
Yes 194 145 5.46 0.000 (4.38, 6.81)
Respiratory exhaustion (n = 11773) Ref = No 2360 9227
Yes 84 102 3.22 0.000 (2.40, 4.31)
Severe dehydration (n = 11773) Ref = No 2373 9240
Yes 71 89 3.11 0.000 (2.27, 4.26)
Previous attendance (n = 11773) Ref = No 2160 8429
Yes 284 900 1.23 0.004 (1.07, 1.42)
Known contact with Covid-19 case (n = 1177 Ref = No 2175 8474
Yes 269 855 1.23 0.006 (1.06, 1.42)
Central capillary refill (n = 2935) Ref = Normal 486 2179
Abnormal 101 169 2.68 0.000 (2.05, 3.49)
https://doi.org/10.1371/journal.pone.0245840.t002
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unrestricted and restricted LASSO models applied to the validation cohort. The c-statistics
(0.82 and 0.81 respectively, compared with 0.80 for the score) indicate the effect of restricting
the number of variables and then developing a score had upon discrimination. Fig 4 shows the
probability of adverse outcome for each value of the score. Table 3 shows the sensitivity and
specificity for predicting outcome at each threshold of the triage tool.
Fig 1. Summary of the derivation process.
https://doi.org/10.1371/journal.pone.0245840.g001
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S3 and S4 Figs show the ROC curves, and S6 and S7 Tables show the predictive perfor-
mance of the score when applied to the secondary outcomes of organ support and death with-
out organ support in the validation cohort. The score provided better prognostic
discrimination for death without organ support (c-statistic 0.83, 95% CI 0.82 to 0.84) than for
organ support (0.68, 95% CI 0.67 to 0.69).
Fig 2. The PRIEST COVID-19 clinical severity score.
https://doi.org/10.1371/journal.pone.0245840.g002
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Discussion
We have developed a clinical illness severity score for acutely ill patients presenting to the ED
with suspected COVID-19 that combines the NEWS2 score, age, sex, and performance status
to predict the risk of death or receipt of organ support in the following 30 days. The score
ranges from zero to 29 points, with a score greater than four predicting adverse outcome with
high sensitivity and low specificity. In developing the score, we tried to optimise usability with-
out compromising performance. Usability was optimised by basing the score on the existing
NEWS2 score and only adding easily available information. The c-statistic of the score on the
validation cohort was 0.80, compared with 0.82 and 0.81 when the unrestricted and restricted
Fig 3. ROC curve for the tool predicting the primary outcome of death or organ support, validation cohort.
https://doi.org/10.1371/journal.pone.0245840.g003
Fig 4. Probability of adverse outcome for each value of the score, validation cohort.
https://doi.org/10.1371/journal.pone.0245840.g004
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models were applied to the validation cohort, suggesting that simplifying the tool did not
excessively compromise prediction.
Our score has a number of features that sets it apart from other scores. Derivation and vali-
dation were rigorously undertaken, following an independently peer-reviewed protocol set up
in advance of the pandemic, using data from a very large and representative cohort presenting
to EDs across the UK, and analysed using a pre-specified statistical analysis plan. Our choice
of adverse outcome ensured that the score predicts need for life-saving intervention, not just
mortality. Our patient selection criteria ensure that the score is applicable to the clinically rele-
vant population of suspected COVID-19 rather than a confirmed cohort, which would typi-
cally be assembled retrospectively and exclude those with diagnostic uncertainty at
presentation. We also included patients who were discharged after ED assessment, which is
essential if the score is to be used to support decision-making around admission or discharge.
Our score improves upon those recommended in existing guidelines for the initial assess-
ment of suspected acute COVID-19, with a c-statistic of 0.8 compared to 0.75 for CURB-65
and 0.77 for NEWS2 and PMEWS [11]. The practical implications of improved prediction can
be appreciated by considering how the addition of age, sex and performance status to NEWS2
might improve decision-making around admission. NEWS2 would suggest that a young per-
son with unlimited performance status and an elderly person with limited performance but
the same NEWS2 score should have the same admission decision, whereas our score






Sensitivity (95% CI) Specificity (95% CI) Positive predictive value (95%
CI)
Negative predictive value (95%
CI)
>0 0.97 1.00 (1.00, 1.00) 0.04 (0.03,0.04) 0.25 (0.24, 0.25) 0.99 (0.98, 1.00)
>1 0.92 1.00 (1.00, 1.00) 0.10 (0.10, 0.10) 0.26 (0.25, 0.26) 0.99 (0.99, 0.99)
>2 0.87 0.99 (0.99, 0.99) 0.17 (0.17, 0.18) 0.27 (0.27, 0.28) 0.99 (0.98, 0.99)
>3 0.80 0.99 (0.98, 0.99) 0.26 (0.26, 0.27) 0.30 (0.29, 0.30) 0.98 (0.98, 0.99)
>4 0.73 0.98 (0.97, 0.98) 0.34 (0.34, 0.35) 0.32 (0.31, 0.32) 0.98 (0.98, 0.98)
>5 0.66 0.95 (0.95, 0.95) 0.43 (0.43, 0.43) 0.34 (0.34, 0.35) 0.96 (0.96, 0.97)
>6 0.59 0.91 (0.91, 0.91) 0.50 (0.50, 0.51) 0.37 (0.36, 0.37) 0.95 (0.94, 0.95)
>7 0.53 0.86 (0.85, 0.86) 0.58 (0.57, 0.58) 0.39 (0.39, 0.40) 0.93 (0.93, 0.93)
>8 0.46 0.80 (0.79, 0.80) 0.65 (0.64, 0.65) 0.42 (0.41, 0.42) 0.91 (0.91, 0.91)
>9 0.40 0.73 (0.72, 0.74) 0.71 (0.71, 0.71) 0.44 (0.44, 0.45) 0.89 (0.89, 0.90)
>10 0.33 0.65 (0.64, 0.66) 0.77 (0.77, 0.77) 0.47 (0.46, 0.48) 0.87 (0.87, 0.88)
>11 0.27 0.57 (0.56, 0.58) 0.82 (0.82, 0.82) 0.50 (0.49, 0.50) 0.86 (0.86, 0.86)
>12 0.21 0.47 (0.46, 0.48) 0.87 (0.87, 0.87) 0.53 (0.53, 0.54) 0.84 (0.84, 0.84)
>13 0.16 0.37 (0.37, 0.38) 0.91 (0.91, 0.91) 0.56 (0.55, 0.57) 0.82 (0.82, 0.82)
>14 0.12 0.29 (0.28, 0.30) 0.94 (0.93, 0.94) 0.59 (0.58, 0.60) 0.81 (0.80, 0.81)
>15 0.09 0.23 (0.22, 0.23) 0.96 (0.95, 0.96) 0.62 (0.61, 0.64) 0.80 (0.79, 0.80)
>16 0.06 0.17 (0.17, 0.18) 0.97 (0.97, 0.97) 0.65 (0.64, 0.67) 0.79 (0.79, 0.79)
>17 0.04 0.12 (0.11, 0.12) 0.98 (0.98, 0.98) 0.68 (0.66, 0.70) 0.78 (0.78, 0.78)
>18 0.03 0.08 (0.07, 0.08) 0.99 (0.99, 0.99) 0.67 (0.65, 0.69) 0.77 (0.77, 0.78)
>19 0.02 0.05 (0.04, 0.05) 0.99 (0.99, 1.00) 0.73 (0.70, 0.76) 0.77 (0.77, 0.77)
>20 0.01 0.03 (0.03, 0.03) 1.00 (1.00, 1.00) 0.76 (0.72, 0.79) 0.77 (0.76, 0.77)
>21 0.01 0.02 (0.02, 0.02) 1.00 (1.00, 1.00) 0.81 (0.76, 0.85) 0.76 (0.76, 0.77)
>22 0.00 0.01 (0.01, 0.01) 1.00 (1.00, 1.00) 0.84 (0.76, 0.90) 0.76 (0.76, 0.77)
>23 0.00 0.01 (0.00, 0.01) 1.00 (1.00, 1.00) 0.87 (0.76, 0.94) 0.76 (0.76, 0.76)
>24 0.00 0.00 (0.00, 0.00) 1.00 (1.00, 1.00) 0.86 (0.66, 0.96) 0.76 (0.76, 0.76)
https://doi.org/10.1371/journal.pone.0245840.t003
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recognises that safe discharge is much more likely to be achieved in the younger patient. Our
score shares similarities with PMEWS, which was developed for the H1N1 influenza pan-
demic, but achieves better prediction by using more detailed age, sex and performance status
data.
Since the start of the pandemic numerous studies have sought to develop and evaluate pre-
diction scores for COVID-19. A living systematic review [14] has identified 50 prognostic
models for adverse outcome in people with diagnosed COVID-19. C-statistics ranged from
0.68 to 0.99, and the most frequently used predictor variables were age, sex, comorbidities,
temperature, lymphocyte count, C reactive protein, creatinine, and imaging features. Recently
the ISARICWHO Clinical Characterisation Protocol developed and validated the 4C Mortal-
ity Score [15] that predicts the mortality risk for people admitted with COVID-19 with better
discriminant performance than 15 pre-existing risk stratification scores (c-statistic 0.77 versus
0.61–0.76).
These scores have important limitations as triage tools, which we have attempted to address
in developing our triage tool. Many were developed to predict mortality, whereas triage tools
need to predict need for life-saving treatment. Most were developed on admitted populations,
whereas the relevant population for an initial assessment tool needs to include those dis-
charged after assessment. This is because the decision to be admit is likely to be based upon
the same predictor variables that are used in the tool, so excluding discharged patients will
underestimate the predictive value of these variables. For example, oxygen saturation is an
important predictor of adverse outcome and is also an important criterion for determining
hospital admission. Developing a triage tool on a population selected on the basis of oxygen
saturation will underestimate the value of oxygen saturation as a predictor. This may explain
why many scores developed on admitted patients do not include well-recognised clinical pre-
dictors. Finally, inclusion of laboratory data as predictor variables prolongs ED stay and pre-
vents the triage tool being used for rapid assessment.
Rapid clinical scores have been proposed or evaluated in several studies. Liao et al [16] pro-
posed adding age>65 years to the NEWS2 score to aid decision-making, based on early experi-
ence of the pandemic in China. Myrstad et al [17] reported a c-statistic of 0.822 (95% CI 0.690
to 0.953) for NEWS2 predicting death or severe disease in a small study (N = 66) of people hos-
pitalised with confirmed COVID-19. Hu et al [18] reported c-statistics of 0.833 (0.737 to
0.928) for the Rapid Emergency Medicine Score (REMS) and 0.677 (0.541 to 0.813) for the
Modified Emergency Medicine Score (MEWS) for predicting mortality in critically ill patients
with COVID-19. Haimovich et al [19] developed the quick COVID-19 severity index, consist-
ing of respiratory rate, oxygen saturation, and oxygen flow rate, which predicted respiratory
failure within 24 hours in adults admitted with COVID-19 requiring supplemental oxygen
with a c-statistic of 0.81 (0.73 to 0.89). These studies are limited by small numbers (producing
imprecise estimates of accuracy), single-centre design (limiting generalisability) and only
including admitted patients.
An important limitation of our study is that retrospective data collection resulted in some
missing and may have resulted in some inaccuracy of predictor variable recording. Recording
of inspired oxygen concentration was subject to a particularly high rate of missing data. We
anticipated this problem and pre-specified analyses involving multiple imputation, determin-
istic imputation, and complete case analysis to explore the impact of missing data. There was
reasonable concordance between the models. Another potential limitation is that our defini-
tion of adverse outcome did not include events occurring after 30 days or requirements for
hospital admission (such as oxygen therapy or intravenous fluids) that fell short of our defini-
tion of organ support. We may also have missed adverse outcomes if patients attended a differ-
ent hospital after initial hospital discharge. This is arguably less likely in the context of a
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pandemic, in which movements between regions were curtailed, but cannot be discounted.
The 5-point scale we used for determining performance status has not been widely used or
evaluated, although the 9-point clinical frailty index maps onto it reasonably well. Finally,
although our triage tool can be used in the prehospital or community setting, we recommend
caution in extrapolating our findings to settings where there is likely to be a lower prevalence
of adverse outcome.
Our clinical score could be used to support ED decision-making around hospital admission
and inpatient referral. Scores of four or less could identify a proportion of patients at low risk
of adverse outcome who would be suitable for discharge home, while a higher threshold could
be used to select patients for critical care. However, triage tools should only support and not
replace clinical decision-making. The clinical context, patient preferences, and available
resources must be considered. This may be illustrated by older patients (especially male) with
limited performance status who score greater than four with little or no physiological abnor-
malities. These patients would not necessarily be at high risk of adverse outcome if they were
managing their symptoms at home but the clinical context is presentation to a hospital ED.
Our data show that if these patients needed ED assessment then they were at significant risk
of adverse outcome even if there was little physiological abnormality. In terms of decision-
making, patient preference should be taken into account, since these patients may accept dis-
charge with a significant risk of adverse outcome if hospital admission provides no clear
benefit.
Our triage tool could also be used to support prehospital and community decision-making
around decisions to refer for hospital assessment. However, the importance of developing
scores in an appropriate population needs to be considered. A score developed on an ED pop-
ulation may be inappropriate for supporting decisions to transport to the ED in the same way
as scores developed on the inpatient population may be inappropriate for supporting admis-
sion decisions in an ED population. Further validation is required to determine the perfor-
mance of the tool in these settings. Further ED validation in subsequent waves of the
pandemic or other ED settings would also be helpful to determine whether changes or differ-
ences in the pandemic population or outcomes lead to changes in outcome prediction.
In summary, we have developed a clinical score that can provide a rapid and accurate
assessment of the risk of adverse outcome in adults who are acutely ill with suspected
COVID-19.
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